Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Common Equity (2016 - 2017)

Historic Common Equity for Bone Biologics (BBLG) over the last 2 years, with Q3 2017 value amounting to -$10.2 million.

  • Bone Biologics' Common Equity fell 4623.88% to -$10.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$10.2 million, marking a year-over-year decrease of 4623.88%. This contributed to the annual value of -$8.4 million for FY2016, which is N/A changed from last year.
  • Bone Biologics' Common Equity amounted to -$10.2 million in Q3 2017, which was down 4623.88% from -$9.7 million recorded in Q2 2017.
  • Bone Biologics' 5-year Common Equity high stood at -$3.2 million for Q1 2016, and its period low was -$10.2 million during Q3 2017.